Hematology Consults

Coagulation Abnormalities

Interpret prolonged PT and aPTT, exclude anticoagulant and specimen interference, use mixing studies appropriately, recognize acquired factor inhibitors, and evaluate disseminated intravascular coagulation.

Audience: internal medicine residents Last reviewed: July 2026

Bedside approach

Answer these questions first

Is the patient bleeding? Assess hemodynamics, hemoglobin trajectory, mucosal bleeding, soft-tissue bleeding, gastrointestinal bleeding, intracranial symptoms, and procedural urgency.
Which test is prolonged? Isolated PT, isolated aPTT, or combined prolongation point toward different pathways.
Could this be medication-related? Review unfractionated heparin, low-molecular-weight heparin, warfarin, direct thrombin inhibitors, factor Xa inhibitors, and recent factor replacement.
Is the sample reliable? Exclude heparin contamination, underfilled citrate tubes, high hematocrit, delayed processing, and specimen clotting.
Deficiency or inhibitor? A mixing study may help after drug and specimen interference have been addressed.
Is this systemic consumption? Review platelets, fibrinogen, D-dimer, smear, organ dysfunction, sepsis, malignancy, trauma, pregnancy, and liver disease.

Urgent escalation

  • Major or critical-site bleeding
  • Rapidly expanding soft-tissue, retroperitoneal, or muscular bleeding
  • Postpartum or postoperative bleeding with isolated prolonged aPTT
  • Suspected acquired hemophilia A
  • Possible acute promyelocytic leukemia with DIC
  • Sepsis, shock, trauma, or malignancy with evolving DIC
  • Marked hypofibrinogenemia with active bleeding
  • Unexplained coagulation abnormality before an urgent invasive procedure

1. Interpret the PT and aPTT pattern

Pattern Important causes Practical next steps
Isolated prolonged PT Factor VII deficiency or inhibitor, early vitamin K deficiency, warfarin, liver disease, DIC, and some factor Xa inhibitors Review medication timing, liver studies, fibrinogen, platelets, D-dimer, and consider a PT mixing study and factor VII assay.
Isolated prolonged aPTT Unfractionated heparin, direct thrombin inhibitor, lupus anticoagulant, factor VIII/IX/XI deficiency, factor VIII inhibitor, factor XII/contact-factor deficiency, or some von Willebrand disease Exclude heparin or DOAC effect, assess bleeding history, then consider mixing study, lupus-anticoagulant testing, factor assays, and Bethesda testing.
Both PT and aPTT prolonged Advanced liver disease, DIC, severe vitamin K deficiency, massive transfusion, common-pathway factor deficiency, supratherapeutic anticoagulation, or multiple abnormalities Review fibrinogen, D-dimer, platelets, liver studies, medication exposure, thrombin time, and mixing studies when appropriate.
Normal PT and aPTT with bleeding Platelet disorder, von Willebrand disease, factor XIII deficiency, vascular disorder, connective-tissue disease, or mild factor deficiency Do not stop the bleeding evaluation because screening clotting times are normal.
Contact-factor deficiencies such as factor XII, prekallikrein, and high-molecular-weight kininogen deficiency can markedly prolong the aPTT without producing a clinical bleeding disorder.

2. Exclude anticoagulant and preanalytic interference

Specimen problems

  • Heparin contamination from a central line or recently flushed catheter
  • Underfilled citrate tube
  • Very high hematocrit without citrate adjustment
  • Clotted or improperly mixed specimen
  • Delayed transport or processing
  • Recent plasma, factor concentrate, or transfusion

Anticoagulant effects

Medication Common testing effect Useful clarification
Unfractionated heparin Usually prolongs aPTT and thrombin time; may affect PT at high levels Anti-Xa assay, thrombin time, reptilase time, medication record, and specimen source
Low-molecular-weight heparin aPTT may be normal or variably prolonged LMWH-calibrated anti-Xa assay when clinically indicated
Warfarin Primarily prolongs PT/INR Medication history, dose timing, INR trend, nutrition, and interacting medications
Direct thrombin inhibitor Often prolongs aPTT and thrombin time; PT effect varies Drug-specific testing when available and medication timing
Direct factor Xa inhibitor PT and aPTT effects are reagent-dependent and may be normal despite clinically relevant drug Drug-calibrated anti-Xa level when available and clinically necessary
A normal PT or aPTT does not reliably exclude a clinically meaningful direct oral anticoagulant concentration.

3. Mixing studies

A standard mixing study combines patient plasma with normal pooled plasma, commonly in a 1:1 ratio. Correction suggests replacement of a missing factor; failure to correct suggests an inhibitor, anticoagulant, or assay interference. Interpretation must use the laboratory’s own correction criteria.

  1. Confirm that the PT or aPTT prolongation is reproducible and clinically meaningful.
  2. Review anticoagulant exposure and exclude heparin contamination.
  3. Perform an immediate mix using the laboratory’s validated protocol.
  4. When a time-dependent factor VIII inhibitor is possible, compare immediate and incubated results.
  5. Direct subsequent testing toward factor assays, lupus-anticoagulant testing, or inhibitor quantification.
Corrects immediately and remains corrected More consistent with factor deficiency. Select factor assays based on whether PT, aPTT, or both are prolonged.
Does not correct Consider lupus anticoagulant, heparin, direct anticoagulant, strong specific factor inhibitor, or another interference.
Corrects initially, then prolongs after incubation Raises concern for a time-dependent inhibitor, classically a factor VIII inhibitor.
Mixing-study correction is not a simple universal percentage. Laboratories may use normal-range correction, an index of circulating anticoagulant, or other validated methods.

4. Lupus anticoagulant versus acquired factor inhibitor

Feature Lupus anticoagulant Acquired factor VIII inhibitor
Typical clinical phenotype Often asymptomatic or thrombotic rather than bleeding New spontaneous bleeding, bruising, soft-tissue, muscular, gastrointestinal, genitourinary, or postpartum bleeding
PT Usually normal Usually normal
aPTT Often prolonged Often isolated and prolonged
Mixing study Usually incomplete correction May show immediate partial correction followed by time-dependent prolongation
Confirmatory testing DRVVT and an aPTT-based lupus-anticoagulant system with screening and phospholipid-dependent confirmation Factor VIII activity and Nijmegen-modified Bethesda inhibitor assay

Acquired hemophilia A red flags

  • New isolated prolonged aPTT
  • No personal or family bleeding history
  • Large spontaneous ecchymoses or soft-tissue hematomas
  • Postpartum bleeding
  • Older adult with unexplained bleeding
  • Low factor VIII activity with an inhibitor

Approximately 10% of patients may initially lack bleeding. Clinically relevant bleeding should be treated urgently in consultation with an experienced hematology or hemophilia center. [oai_citation:1‡Haematologica](https://haematologica.org/article/view/9931)

5. Vitamin K deficiency, liver disease, and DIC

Feature Common interpretation Cautions
Vitamin K deficiency PT often rises first because factor VII has a short half-life; severe deficiency may prolong both PT and aPTT Review nutrition, antibiotics, biliary disease, malabsorption, warfarin, and response to replacement.
Advanced liver disease PT and aPTT may be prolonged with thrombocytopenia and variable fibrinogen PT/INR does not fully measure bleeding risk in cirrhosis. Hemostasis may be rebalanced, with both bleeding and thrombosis possible.
DIC Falling platelets, increased fibrin-related markers, prolonged PT, and declining fibrinogen in an appropriate clinical setting No single laboratory value diagnoses DIC. Trends and the underlying disorder matter.
Do not use factor VIII alone to distinguish DIC from liver disease. Factor VIII can be influenced by endothelial activation, inflammation, consumption, and assay conditions.

6. Disseminated intravascular coagulation

DIC is an acquired systemic process driven by an underlying disorder such as sepsis, trauma, malignancy, obstetric catastrophe, severe tissue injury, or vascular abnormality. Management depends primarily on treating that trigger.

Common findings

  • Progressive thrombocytopenia
  • Markedly elevated D-dimer or fibrin-related markers
  • Prolonged PT, with variable aPTT
  • Falling fibrinogen, although it may initially remain normal or high
  • Schistocytes may be present but are not required
  • Bleeding, thrombosis, organ dysfunction, or both
Fibrinogen is an acute-phase reactant. A “normal” fibrinogen does not exclude evolving DIC when the value is rapidly declining from a much higher baseline.

Management principles

  • Treat the underlying disorder immediately.
  • Trend platelets, PT, fibrinogen, D-dimer, hemoglobin, and organ function.
  • Use blood components for active bleeding, critical deficiency, or procedure-related need—not solely to normalize laboratory values.
  • Evaluate thrombosis risk and the possible role of anticoagulation with specialist input.
  • Follow obstetric, trauma, massive-transfusion, leukemia, or sepsis pathways when applicable.

Interactive tool

Classic ISTH overt-DIC score

Use this score only in a patient with an underlying disorder known to be associated with DIC. A score of at least 5 supports overt DIC in the classic scoring system.

Select all four components.

“Moderate” and “strong” fibrin-marker increases depend on the local assay and laboratory reference framework. The ISTH published an updated DIC definition and scoring proposal in 2025; verify which criteria your institution has adopted.

7. Resident summary

  1. Determine whether PT, aPTT, or both are prolonged.
  2. Assess the patient’s bleeding, thrombosis, and procedural urgency.
  3. Exclude anticoagulants, heparin contamination, and specimen problems before interpreting a mixing study.
  4. Correction with mixing favors deficiency; noncorrection favors an inhibitor or drug effect.
  5. A time-dependent inhibitor pattern with new bleeding raises concern for acquired hemophilia A.
  6. Lupus anticoagulant usually signals thrombosis risk rather than a bleeding disorder.
  7. Normal PT and aPTT do not exclude von Willebrand disease, platelet dysfunction, or factor XIII deficiency.
  8. Diagnose DIC from the clinical context, serial laboratory pattern, and underlying trigger—not one abnormal result.

8. Knowledge check

Question 1

A patient has an isolated prolonged aPTT. Blood was drawn from a heparinized central line. What is the best next step?

Question 2

An isolated prolonged aPTT fully corrects in an immediate mixing study and remains corrected after incubation. What is most likely?

Question 3

An older adult without a prior bleeding history develops large spontaneous hematomas and an isolated prolonged aPTT. The mixing study shows time-dependent inhibition. What diagnosis is most concerning?

Question 4

Which statement about lupus anticoagulant is most accurate?

Question 5

A septic patient has falling platelets, rapidly increasing D-dimer, PT prolongation, and fibrinogen that has fallen from 650 to 220 mg/dL. What is the best interpretation?

References

  1. ARUP Consult. Prolonged Clotting Time Evaluation. Open resource
  2. Santoro RC, et al. Isolated Prolongation of Activated Partial Thromboplastin Time: Not Just Bleeding Risk! Medicina. 2023. Free full text
  3. Favaloro EJ. Testing for the lupus anticoagulant: the good, the bad, and the ugly. 2024. Free full text
  4. Tiede A, et al. International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica. 2020. Free full text
  5. Iba T, et al. Updated definition and scoring of disseminated intravascular coagulation: communication from the ISTH SSC. 2025. Open article
  6. International Society on Thrombosis and Haemostasis. DIC guidance and bibliography. ISTH resource

Educational disclaimer

This guide is intended for clinician education and does not replace institutional coagulation-laboratory methods, hematology consultation, transfusion-service guidance, anticoagulant-reversal protocols, or individualized clinical judgment. Major bleeding, possible acquired hemophilia, acute promyelocytic leukemia, and evolving DIC require urgent local escalation.